I was among the many who didn't even know about Nuremberg trials for the vaxx. If I had heard of it, I had forgotten about it. But guess what the media didn't do. They didn't make it a front page item for the world to see. It should prove interesting.
Judge Orders Nuremberg Public Hearing on Nov 9, For Illegality Of Covid-19 Vaccines!
https://therepublicansvoice.com/united-states/public-hearing-for-illegality-of-covid19/September 13, 2023 the Appellate judge ordered a date for an oral hearing on our appeal to stop the injections! All it took was a few months to get it to the right Appellate court after it got lost in the Costa Rica system. The appeal is to stop the covid-19 vaccine entirely off the market.
We were afraid the appeal would be denied for being late due to the courts online upload technical glitches and then our appeal documents literally disappearing (cyber polygon?) so we had to call and ask the clerks to figure it out. The clerks gave us an address to mail to so we printed a ton of pages and delivered the documents late.
...
The people are waking up. Will they awaken enough that they will realize that it was partially their own elected government people who destroyed their lives with the vaxxes?
Pfizer CUTS COSTS after significant decline in uptake of COVID-19 vaccine and Paxlovid
https://www.naturalnews.com/2023-10-19-pfizer-cuts-costs-decline-covid-medication-uptake.htmlVaccine giant Pfizer has been forced to implement cost-cutting measures after a significant decline in the uptake of its Wuhan coronavirus (COVID-19) vaccine and medication over the past 12 months.
According to a Pharmaphorum report, the New York-based pharmaceutical firm is set to cut costs by $1 billion this year and at least $2.5 billion in 2024 – amounting to a rough total of $3.5 billion. Pfizer recorded an annual revenue of more than $100 billion in 2022, with sales of its mRNA COVID-19 injection comprising $56 million of that total.
Now, it projects a much lower revenue for 2023 ranging between $58 billion and $61 billion. The company has not provided any indication of the total jobs to be cut, however.
Pfizer's reduced revenue stemmed from lower sales of its COVID-19 injection and antiviral drug Paxlovid. It projects sales for these to hit $12.5 billion, roughly $9 billion lower than its initial forecast. The U.S. government's return of 7.9 million Paxlovid treatment courses at the end of 2023 as part of an amended supply agreement, alongside other factors, slashes expected revenues for the antiviral drug.
"The return is on a non-cash basis, so the U.S. government will have a credit note that will be redeemable for Paxlovid supplied in [the] future," wrote Pharmaphorum. "The U.S. will keep an ongoing stockpile of one million Paxlovid courses that will be refreshed as it expires, until 2028."
"For now, the drug has been made available under emergency use authorization (EUA), but a full marketing application was approved earlier this year. The commercial transition will begin in November as the government begins to discontinue the distribution of EUA-labelled Paxlovid. The drug will be made available to people with private health insurance from the start of next year, said Pfizer."
"We remain proud that our scientific breakthroughs played a significant role in getting the global health crisis under control," Pfizer CEO Albert Bourla said following the announcement. "As we gain additional clarity around vaccination and treatment rates for COVID, we will be better able to estimate the appropriate level of supply to meet demand."
Pfizer could go BANKRUPT, warns Igor Chudov...